Eileen Marshall

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Cooley advised Uber Technologies (NYSE: UBER), a technology platform that uses a massive network, top technology, operational excellence and deep product knowledge to power movement from Point A to Point B, on its offering of $1 billion principal amount of 0% exchangeable senior notes due 2028.

Cooley advised Datadog (Nasdaq: DDOG), a monitoring and security platform for cloud applications, on its acquisition of Eppo, a feature flagging and experimentation platform that will tightly integrate with Datadog’s existing product analytics suite.

Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.